Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates

Separations - Switzerland
doi 10.3390/separations6010001
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

AGS67E, an Anti-Cd37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

The Promise of Antibody–Drug Conjugates

New England Journal of Medicine
Medicine
2012English

Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2014English

Site-Specific Antibody Drug Conjugates for Cancer Therapy

mAbs
AllergyImmunology
2013English

Efficacy of an Anti-Cd22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B-Cell Acute Lymphoblastic Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Antibody-Drug Conjugates in Bladder Cancer

Bladder Cancer
OncologyUrology
2018English

Antibody – Drug Conjugates (ADC) – Drug Discovery Today: Technologies

Drug Discovery Today: Technologies
BiotechnologyDrug DiscoveryMolecular Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy